Angle PLC - Surrey, England-based medical diagnostics company - Says proof of concept study shows that both circulating tumour cells and cell-free circulating tumour DNA can be analysed from a single blood sample. ‘The results show that removal of plasma from blood samples for circulating tumour DNA analysis does not impact on the number or quality of circulating tumour cells which can be successfully isolated from the same sample using the Parsortix system,’ it explains.

By combining CTC isolation with plasma removal for ctDNA analysis from one sample, it opens the possibility for labs to expand the clinical utility of assays, and make the most of each patients sample.

‘Angle believes there will be significant demand from biopharma companies for an assay that combines ctDNA and CTCs. The workflow presented, demonstrating effective CTC isolation utilising the Parsortix system with concurrent removal of plasma for ctDNA analysis, puts Angle in a highly competitive position in this emerging arena,’ it says.

Current stock price: 46.75 pence, down 1.6% on Monday in London

12-month change: down 62%

Copyright 2022 Alliance News Limited. All Rights Reserved.